（编辑 楚丽君） 证券日报网讯 8月7日晚间，国药现代发布公告称，近日，公司全资子公司国药集团工业有限公司收到 国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》，批准原料药盐酸氯胺酮上市申 请。 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-061 上海现代制药股份有限公司 关于全资子公司获得化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团工 业有限公司（以下简称国药工业）收到国家药品监督管理局核准签发的《化学原 料药上市申请批准通知书》，批准原料药盐酸氯胺酮上市申请，现将相关情况公 告如下： 一、化学原料药基本信息 化学原料药名称：盐酸氯胺酮 登记号：Y20240000546 通知书编号：2025YS00674 化学原料药注册标准编号：YBY67872025 包装规格：1.5kg/桶、2kg/桶、4.5kg/桶 生产企业：国药集团工业有限公司廊坊分公司 企业地址：廊坊经济技术开发区创业路 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、子公司信息 1、公司名称：国药集团工业有限公司 注册地址：北京市顺义 ...

盐酸氯胺酮制剂是一种静脉麻醉药，可作为单一麻醉剂用于无需骨骼肌松弛的诊断和外科手术，也可用 于诱导全身麻醉或者作为其他麻醉剂的补充。 智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团工业有限公司(简称 国药工业)收到国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》，批准原料药盐酸 氯胺酮上市申请。 ...

国药现代公告，全资子公司国药集团工业有限公司收到国家药品监督管理局核准签发的《化学原料药上 市申请批准通知书》，批准原料药盐酸氯胺酮上市申请。盐酸氯胺酮制剂是一种静脉麻醉药，可作为单 一麻醉剂用于无需骨骼肌松弛的诊断和外科手术，也可用于诱导全身麻醉或者作为其他麻醉剂的补充。 目前盐酸氯胺酮原料药登记状态为"A"的国内企业还有安徽万和制药有限公司、江苏恒瑞医药股份有限 公司。国药工业用于该项目的累计研发投入约752.1万元。 ...

Group 1 - Gao Ling Information announced that three shareholders plan to reduce their holdings by a total of up to 2.42% of the company's shares due to personal funding needs [1] - The shareholders include Zhuhai Hengqin New Area Zixiao Investment Partnership, Zhuhai Hengqin New Area Qucheng Investment Partnership, and Zhuhai Huajin Lingyue Intelligent Manufacturing Industry Investment Fund [1] - Gao Ling Information specializes in the R&D, production, and sales of telecommunications network communication equipment, environmental IoT application products, and network and information security products [1] Group 2 - Anglikang has only one innovative drug project under research, ALK-N001, which is currently in Phase I clinical trials [2] - The company is also considering a new innovative drug pipeline project, ALK-N002, which is still in the candidate selection phase [2] - Anglikang focuses on the production and manufacturing of pharmaceuticals, including chemical raw materials and preparations [2] Group 3 - Qixiang Tengda announced the completion of maintenance and technical upgrades for its 300,000 tons/year propylene oxide facility, which has resumed normal production [3] - The company operates in the chemical manufacturing and supply chain management sectors [3] Group 4 - Delisi signed a strategic cooperation agreement with Xiamen Haifusheng Food Group and Xin Sanhe Food Co., Ltd. to collaborate in product supply, market expansion, and technology [4] - Delisi specializes in the production and sales of frozen meat and related products [4] Group 5 - Jinlang Technology's application for issuing convertible bonds has been approved by the Shenzhen Stock Exchange [5] - The company is engaged in the R&D, production, and sales of string inverters [5] Group 6 - Lingyi Zhi Zao plans to acquire a 66.46% stake in Jiangsu Keda through a combination of issuing convertible bonds and cash [6] - The company provides comprehensive intelligent manufacturing services and solutions [6] Group 7 - Jinshi Technology intends to publicly transfer 100% equity of its wholly-owned subsidiary, Hunan Jinshi Technology [7] - The company focuses on digital sanitation, water ecology, and solid waste disposal [7] Group 8 - Qidi Environment announced that 2 million shares held by shareholder Sander Group have been transferred through judicial auction [8] - The company operates in the environmental management sector [8] Group 9 - Guang'an Aizhong expects a reduction in net profit of approximately 39.38 million due to the implementation of a low valley electricity price policy [9] - The company is involved in power generation, supply, and natural gas supply [9] Group 10 - Kangyuan Pharmaceutical received a drug registration certificate for its proprietary product, Canpu Granules, used for treating chronic pelvic pain [10] - The company specializes in the R&D, production, and sales of pharmaceuticals [10] Group 11 - Changqing Technology announced that two shareholders plan to reduce their holdings by up to 5.98% due to personal funding needs [11] - The company focuses on rail transit and building decoration businesses [11] Group 12 - Huaren Pharmaceutical's shareholder plans to reduce its holdings by up to 1% of the company's total shares [12] - The company is a state-controlled pharmaceutical health industry group [12] Group 13 - Jinkai New Energy announced the completion of the first phase of an AI computing power technology service contract [13] - The company is involved in the development, investment, construction, and operation of renewable energy power [13] Group 14 - Sany Heavy Industry has repurchased a total of 72.6792 million shares, amounting to 1.355 billion [14] - The company specializes in the R&D, manufacturing, and sales of engineering machinery [14] Group 15 - Chip导科技 plans to acquire 100% of Shunlei Technology and 17.15% of Shunlei Technology through convertible bonds and cash [15] - The company focuses on the R&D and sales of power semiconductors [15] Group 16 - Tuo Shan Heavy Industry reported that its recent operating conditions are normal, with no significant changes in the internal and external business environment [16] - The company specializes in the R&D, design, production, and sales of engineering machinery components [16] Group 17 - Chang'an Automobile reported a July sales figure of 210,600 vehicles, a year-on-year increase of 23.43% [17] - The company is engaged in the R&D, manufacturing, and sales of vehicles and engines [17]

Group 1 - The animal vaccine sector experienced a decline of 0.39% as of the market close on August 4, ranking among the top losers in concept sectors [1][2] - Within the animal vaccine sector, notable declines were observed in stocks such as Kexing Pharmaceutical, Shenlian Biological, and Kanghua Biological, while 11 stocks saw price increases, with notable gains from Biological Shares, Jinhai Biological, and Weilan Biological, which rose by 2.70%, 2.51%, and 2.10% respectively [1][2] - The animal vaccine sector faced a net outflow of 45 million yuan in principal funds today, with 14 stocks experiencing net outflows, led by Kanghua Biological with a net outflow of 34.6 million yuan [2][3] Group 2 - The top gainers in the concept sectors today included the military equipment restructuring concept, which rose by 5.68%, and military-civilian integration, which increased by 3.53% [2] - The stocks with the highest net inflows in the animal vaccine sector included Jinhai Biological, Guoyao Modern, and Biological Shares, with net inflows of 53.99 million yuan, 11.44 million yuan, and 9.32 million yuan respectively [2][3] - The stock Kanghua Biological had a trading volume turnover rate of 6.20% and a price drop of 2.67%, indicating significant trading activity despite the decline [3]

Group 1 - The core point of the article is the resignation of Mr. Li Xianlin from his position as Vice President of China National Pharmaceutical Group Modern (国药现代) due to reaching retirement age, and he will not hold any positions in the company or its subsidiaries after his departure [2]. Group 2 - For the fiscal year 2024, the revenue composition of China National Pharmaceutical Group Modern is as follows: formulations account for 49.84%, intermediates and active pharmaceutical ingredients account for 47.53%, other businesses account for 2.44%, and health-related businesses account for 0.19% [2].

Group 1 - The company announced the resignation of Vice President Li Xianlin due to reaching retirement age [1] - Li Xianlin's resignation will take effect upon delivery of his resignation report to the board of directors, and he will not hold any positions in the company or its subsidiaries thereafter [1] - The resignation is not expected to impact the company's normal production and operations [1]

Group 1 - The company announced the resignation of Vice President Li Xianlin due to reaching retirement age, effective immediately upon submission of his resignation [1] - Li Xianlin will not hold any positions in the company or its subsidiaries after his resignation [1] - The resignation is not expected to impact the company's normal production and operations [1] Group 2 - Li Xianlin's original term was set to expire in November 2025, but he is leaving earlier due to retirement [1] - The company assures that there are no false records or misleading statements in the announcement [1] - The resignation complies with the relevant laws and company regulations [1]

Group 1 - The core point of the article is the resignation of Li Xianlin, the Vice President of China National Pharmaceutical Group Modern (600420), due to reaching retirement age [1] - Li Xianlin has submitted a written resignation application and will leave his position on August 3, 2025 [1] - He will also resign from all other positions held in the company and its subsidiaries [1]